History of the Discovery and Clinical Introduction of Chlorpromazine

Reference

• L–pez-Mu–oz F, Alamo C, Cuenca E: Farmacos antipsic–ticos. In: L–pez-Mu–oz F, Alamo C, eds. Historia de la Neuropsicofarmacolog–a. Una nueva aportaci–n a la terap–utica farmacol–gica de los trastornos del Sistema Nervioso Central. Madrid: Ediciones Eurobook, S.L. and Servicio de Publicaciones de la Universidad de Alcal–, 1998:207–243
   Google Scholar
• Laborit H, Huguenard P, Alluaume R: Un nouveau stabilisateur v–g–tatif (le 4560 RP). Presse M–d 1952; 60:206–208
   Google Scholar
• Delay J, Deniker P, Harl JM: Utilisation en th–rapeutique d–une ph–nothiazine d–action centrale selective (4560 RP). Ann M–d Psychol 1952; 110:112–117
   Google Scholar
• Bein HJ: Zur Pharmakologie des reserpin, eines neuen alkaloids aus rauwalfia serpentina bent. Experientia 1954; 9:107–110
   Google Scholar
• Kline NS: Use of rauwolfia serpentina bebth in neuropsychiatric conditions. Ann New York Acad Sci 1954; 59:107–132
   Google Scholar
• Prince R: The use of Rauwolfia for the treatment of Psychosis by Nigerian native doctors. Am J Psychiatry 1960; 117:147–149
   Google Scholar
• Cade JFJ: Lithium salts in the treatment of psychotic excitement. Med J Austral 1949; 2:349–352
   Google Scholar
• Caldwell AE: History of psychopharmacology. In: Clark WG, Del Giudice J, eds. Principles of Psychopharmacology. New York: Academic Press, 1970: 9–30
   Google Scholar
• Jacobsen E: The early history of psychotherapeutic drugs. Psychopharmacology 1986; 89:138–144
   Google Scholar
• Deniker P: From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics). Psychiatr J Univ Ottawa 1989; 14:253–259
   Google Scholar
• Lehmann HE: The introduction of chlorpromazine in North America. Psychiatr J Univ Ottawa 1989; 14:263–265
   Google Scholar
• Ayd FJ: The early history of modern psychopharmacology. Neuropsychopharmacology 1991; 5:71–84
   Google Scholar
• Frankenburg FR: History of the development of antipsychotic medication. Psychiatr Clin North Am 1994; 17:531–540
   Google Scholar
• Shepherd M: Neurolepsis and the psychopharmacological revolution: Myth and reality. Hist Psychiatry 1994; 5:89–96
   Google Scholar
• Healy D: The Psychopharmacologists. New York: Chapman and Hall, 1996
   Google Scholar
• Healy D: The Psychopharmacologists II. London: Arnold, 1999
   Google Scholar
• Healy D: The Psychopharmacologists III. London: Arnold, 2000
   Google Scholar
• Lehmann HE, Ban TA: The history of the psychopharmacology of schizophrenia. Can J Psychiatry 1997; 42:152–163
   Google Scholar
• L–pez-Mu–oz F, Alamo C, Cuenca E: La –D–cada de Oro– de la Psicofarmacolog–a (1950–1960): Trascendencia hist–rica de la introducci–n cl–nica de los psicof–rmacos cl–sicos, Psiquiatria. COM (electronic journal), Sep (cited 7 Jan 2001), 4 (3), URL: http://www.psiquiatria.com/psiquiatria/revista/47/1800/?++interactivo, 2000
   Google Scholar
• Shen WW: A history of antipsychotic drug development. Compr Psychiatry 1999; 40:407–414
   Google Scholar
• Cancro R: The introduction of neuroleptics: A psychiatric revolution. Psychiatr Serv 2000; 51:333–335
   Google Scholar
• Ban TA: Pharmacotherapy of mental illness. A historical analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 2001; 25:709–727
   Google Scholar
• Altschule MD: Use of chlorpromazine and reserpine in mental disorders. New Eng J Med 1956; 254:515–519
   Google Scholar
• Ey H, Faure H: Les diverses m–thodes d–emploi de la chlorpromazine en th–rapeutique psychiatrique et leurs indications. L–Enc–phale 1956; Num–ro Sp–cial:61–71
   Google Scholar
• L–pez-Mu–oz F, Alamo C, Rubio G, Cuenca E: Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology. Prog Neuro-Psychopharmacol Biol Psychiatry 2004; 28:205–208
   Google Scholar
• Alamo C, L–pez-Mu–oz F, Cuenca E: El desarrollo de la clozapinay su papel en la conceptualizaci–n de la atipicidad antipsic–tica, Psiquiatria.COM (electronic journal), Sep (cited 7 Jan 2001), 4 (3), URL: http://www.psiquiatria.com/psiquiatria/revista/47/1801/?++interactivo, 2000
   Google Scholar
• Shorter E: A History of Psychiatry. In: From the Era of Asylum to the Age of Prozac. New York: John Wiley & Sons, Inc., 1997
   Google Scholar
• Lickey ME, Gordon B: Medicamentos para las enfermedades mentales. Barcelona: Labor, 1986: 78
   Google Scholar
• Swazey JP: Chlorpromazine in Psychiatry. In: A Study of Thera-peutic Innovation. Cambridge: MIT Press, 1974
   Google Scholar
• Zircle CL: To tranquilizers and antidepressants: From antimalari-als and antihistamines. In: Clarke FH, ed. How Modern Medicines are Discovered. Mt. Kisco: Futura, 1973:55–77
   Google Scholar
• Gilman H, van Ess PR, Shirley DA: The metalation of 10-phenylphenothiazine and of 10-ethyl-phenothiazine. J Am Chem Soc 1944; 66:1214–1216
   Google Scholar
• Daumezon G, Cassan L: essai de thérapeutique abortive d'acces maniaco-dépressifs par le 2339 RP. Ann Med Psychol 1943; 101:432–435
   Google Scholar
• Guiraud P, David C: Traitement de Pagitation motrice par un anti-histaminique (3277 RP). Comptes Rendus du 48 Congres des Médecins Aliénistes et des Neurologistes de Langue Francaise, 1950:599–602
   Google Scholar
• Laborit H: Reaction organique a l 'agression et choc. Paris: Masson & Cie, 1952
   Google Scholar
• Thuillier J: Naissance de la psychopharmacologie ou "une histoire de nez". Urgences 1994; 1–2:21-22
   Google Scholar
• Thuillier J: El nuevo rostro de la locura. Barcelona: Planeta, 1981:107–155
   Google Scholar
• Courvoisier S, Fournel J, Ducrot R et al: Propiétés pharmacody-namiques du chlorhydrate de chloro-3 (dimethypamine 3 'propy1)-10 phénotiazine (4560RP). Arch Int Pharmacodyn Ther 1953; 92:305–361
   PubMedGoogle Scholar
• Courvoisier S: Pharmacodynamic basis for the use of chlorprom-azine in psychiatry. J Clin Exp Psychopathol 1956; 17:25–37
   PubMedGoogle Scholar
• Laborit H, Huguenard P: L'hibernation artificielle par moyens pharmacodynamiques of physiques. Presse Med 1951; 59:1329
   PubMed Web of Science ®Google Scholar
• Chertock L: 30 ans apres: la petite histoire de la découverte des neuroleptiques. Ann Med Psychol 1982; 140:971–974
   Google Scholar
• Laborit H, Jaulmes C, Bénitte A: Certain experimental aspects of artificial hibernation. Anest Analg 1952; 9:232
   Google Scholar
• Hamon J, Paraire J, Velluz J: Remarques sur l'action du 4560RP sur Pagitation maniaque. Ann Med Psychol 1952; 110:332–335
   Google Scholar
• Shen WW, Giesler MC: The discoverers of the therapeutic effect of chlorpromazine in psychiatry: Qui étaient les vrais premiers practiciens? Can J Psychiatry 1998; 43:423–424
   Google Scholar
• Delay J, Deniker P: 38 cas de psychoses traitées par la cure pro-longée et continue de 4560RP. Comptes Rendus du 50 Congres des Médecins Aliénistes et Neurologistes de Langue Francaise 1952:503–513
   Google Scholar
• Ginestet D: Les neuroleptiques. Développement et situation actu-elle. L 'Enc éphale 1991; XVII:149–152
   Google Scholar
• King C, Voruganti LN P: What's in a name? The evolution of the nomenclature of antipsychotic drugs. Rev Psychiatry Neurosci 2002; 27:168–175
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P. Harl JM: Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hiber-nothérapie. Ann Med Psychol 1952; 110:267–273
   PubMedGoogle Scholar
• Delay J, Deniker P. Harl JIM, Grasset A: Traitements des états confusionnels par le chlorte de deméthylaminoprppyl-N-chloro-phénothiazine (4560 RP). Ann Med Psychol 1952; 110:398–403
   Google Scholar
• Delay J, Deniker P: Le traitement des psychoses par une méthode neurolytique dérivée de Phibernotherapie (le 4560 RP utilise seul en cure prolongée et continue). Comptes Rendus du 50 Congres des Médecins Aliénistes et Neurologistes de Langue Francaise 1952; 495–502
   Google Scholar
• Delay J, Deniker P: Reactions biologiques observées au cours du traitement par le chlorte de deméthylaminoprppyl-N-chlorophénothiazine. Comptes Rendus du 50 Congres des Médecins Aliénistes et Neurologistes de Langue Francaise, 1952; 514–518
   Google Scholar
• Pichot P: The discovery of chlorpromazine and the place of psy-chopharmacology in the history of the psychiatry. In: Healy D, ed. The Psychopharmacologists. New York: Chapman and Hall, 1996: 1–27
   Google Scholar
• Sigwald J, Bouttier D: Le chlorhydrate de chloro-3(diméthy-lamino-3-propy1)-10-phéno-thiazine en pratique neuro-psychi-atrique courante. Ann Med 1953; 54:150–184
   Google Scholar
• Deschamps A: Hibernation artificielle en psychiatrie. Presse Med 1952; 60:944–946
   Google Scholar
• Lempériere T: In the beginning in Paris. In: Healy D, ed. The Psy-chopharmacologists II. London: Arnold, 1999:1–15
   Google Scholar
• Healy D: The Antidepressant Era. Cambridge: Harvard Univer-sity Press, 1997
   Google Scholar
• Perrin J, Toulet M: Utilisation de la chlorpromazine dans le traite-ment des psychoses chroniques. L 'Encéphale 1956; Numéro Special: 910–918
   Google Scholar
• Revol L: La thérapeutique par la chlorpromazine en pratique psychiatrique. Paris: Masson et Cie: 1956
   Google Scholar
• Lambert PA: Chlorpromazine: A true story of the progress effected by this drug. In: Ban TA, Healy D, Shorter E, eds. The Rise of Psychopharmacology and the Story of CI1VP. Budapest: Animula Publishing House, 1998:237–243
   Google Scholar
• Battegay R: Forty-four years of psychiatry and psychopharmacology. In: Healy D, ed. The Psychopharmacologists III London: Arnold, 2001:371–394
   Google Scholar
• Labhardt F: Die largactiltherapie bei schizophrenien und anderen psychotischen störungen. Schw Med Wochensch 1953; 60:206–208
   Google Scholar
• Labhardt F: Die ergebnisse der Largactil-behandlung schizophr-ener von 1953 bis 1955 an der Basler Psychiatrischen Univer-sitatsklinik. Schw Arch NeurolPsychiatr 1957; 79:355–389
   Google Scholar
• Elkes J, Elkes C: Effects of chlorpromazine on the behaviour of chronically overactive psychotic patients. Br Med J1954; 2:560–565
   PubMedGoogle Scholar
• Gonzalez Moncles E: Tratamientos farmacolegicos y biolegicos en los inicios de la clinica psiquiatrica universitaria del Profesor Sarre. In: Anton P, coord. Medio Siglo de Psiquiatria en Espalia. Madrid, ELA, 1992:81–83
   Google Scholar
• Griffin DM: An historic oversight. Can Psychiatr Assoc Bull 1994; 26:5
   Google Scholar
• Sarwer-Forner GJ: Personal reminiscences of the early days of psychopharmacology. In: Ban TA, Healy E, Shorter E, eds. The Rise of Psychopharmacology and the Story of CI1VP. Budapest: Animula Publishing House, 1998:32–35
   Google Scholar
• Azima H, Ogle W: Effects of Largactil in mental syndrome. Can Med Assoc J1954; 71:116–121
   PubMed Web of Science ®Google Scholar
• Lehmann HE, Hanrahan GE: Chlorpromazine, new inhibiting agent for psychomotor excitement and manic states. Arch Neurol Psychiatry 1954; 71:227–237
   PubMedGoogle Scholar
• Lehmann HE: A clinical psychopharmacologist remember and takes stock. In: Morgan DW ed. Psychopharmacology: Impact on Clinical Psychiatry. St. Louis: Ishiyaku EuroAmerica, Inc. Pub-lishers, 1985:259–266
   Google Scholar
• Cook L: Pharmacology, behaviour and chlorpromazine.. In: Healy D, ed. The Psychopharmacologists II. London: Arnold, 1999:17–38
   Google Scholar
• Pichot P:d6nde se dirige la psicofarmacologia? In: GutierrezM, Ezcurra J, Pichot P. eds. Avances en Psicofarmacologia. Barcelona: J.R. Prous S.A., 1994:1–15
   Google Scholar
• Winkelman NW: Chlorpromazine in the treatment of neuropsy-chiatric disorders. J Am Med Assoc 1954; 155:18–21
   PubMed Web of Science ®Google Scholar
• Bower WH: Chlorpromazine in psychiatric illness. New Eng J Med 1954; 251:689–692
   Google Scholar
• Cohen IM, Archer JD: Liver function and hepatic complications in patients receiving chlorpromazine. J Am Med Assoc 1955; 159:99–101
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P: Chlorpromazine and neuroleptic treatments in psychiatry. J Clin Exp Psychophatol Quart Rev Psychiatry Neurol 1956; 13:19–24
   Google Scholar
• Rees WL: A controlled trial of chlorpromazine in the manage-ment of patients suffering from asthma associated with anxiety and tension symptoms. L 'Encéphale 1956; Numéro Special: 255–261
   Google Scholar
• Lopez Thor JJ: Estudios sobre la esquizofrenia. Actas Luso-Esp Neurol Psiquiatria 1958; 17:107–125
   Google Scholar
• Berger PA: Medical treatment of mental illness. Science 1978; 200:974–981
   PubMed Web of Science ®Google Scholar
• Davis JM, Cole JO: Fármacos antipsicOticos. In: Freedman AM, Kaplan HI, Sadock BJ, eds. Tratado de Psiquiatria. Barcelona: Editorial Salvat, 1982
   Google Scholar
• Geller JL: The last half-century of psychiatric services as reflected in Psychiatric Services. Psychiatr Serv 2000; 51:41–67
   PubMed Web of Science ®Google Scholar
• Smith Kline and French Laboratories: Ten Year's Experience with Thorazine. Philadelphia: SKF: 1964
   Google Scholar
• Jarvik ME: Drug used in the treatment of psychiatric disor-ders. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics, 4th edition. New York: Macmillan, 1970:151–203
   Google Scholar
• Hollister LE: Farmacologia clinica de drogas psicoterapéuticas. Madrid: Editorial Médica Panamericana S.A, 1982
   Google Scholar
• Casey IF, Bennett IF, Lindley CJ et al: Drug therapy in schizo-phrenia: a controlled study of the relative effectiveness of chlor-promazine, promazine, phenobarbital and placebo. Arch Gen Psychiatry 1960; 2:210–220
   PubMed Web of Science ®Google Scholar
• Casey JF, Lasky JJ, Klett CJ, Hollister LE: Treatment of schizo-phrenia reactions with phenothiazine derivates. Am J Psychiatry 1960; 117:97–105
   PubMed Web of Science ®Google Scholar
• Cole JO, and the NIMH Psychopharmacology Service Center Collaborative Study Group: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10:246–261
   PubMed Web of Science ®Google Scholar
• Hollister LE: From hypertension to psychopharmacology, a ser-endipitous career. In: Healy D, ed. The Psychopharmacologists London: Arnold, 1999:215–236
   Google Scholar
• May PRA: Treatment of Schizophrenia. New York: Science House, 1968
   Google Scholar
• May PRA, Tuma AH, Dixon WJ: Schizophrenia: A follow up study of the results of 5 forms of treatment. Arch Gen Psychiatry 1981; 38:776–784
   PubMedGoogle Scholar
• McKenna PJ, Bailey PE: The strange story of clozapine. Br J Psy-chiatry 1993; 162:32–37
   Web of Science ®Google Scholar
• Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995; 52:173–188
   PubMed Web of Science ®Google Scholar
• Terzian H: Etude de l'action du Largactil (4560 R.P.) et du Pendi-omide sur l'activité électrique cérébrale du lapin. Rev Neurol 1954; 91: 445–453
   Google Scholar
• Terzian H: Etude électro-encephalographique de l'action centrale de la chlorpromazine. Sem 116pitaux Paris 1954; 14:838–841
   Google Scholar
• Hiebel G, Bonvallet M, Dell P: Action de la chlorpromazine (Largactil, 4560 RP) au niveau du systeme nerveux central. Sem 116pitaux Paris 1954; 30:2346–2353
   Google Scholar
• Dell P, Bonvallet M, Hugelin A: Demonstration d'un mécanisme adrénergique au niveau des formations réticuldes du tronc cerebral. Consequences pharmacologiques et psychopatholo-gigues. L 'Encéphale 1956; Numéro Spécia1:819–823
   Google Scholar
• Berthier C, Bonneru-Couchoud M: Problemes d'intégration psycho-biologique soulevés par l'utilisation de la chlorprom-azine. L 'Encéphale 1956; Numéro Spécia1:850–856
   Google Scholar
• Decourt P: Mécanisme d'action de la thérapeutique narcobi-otique en general, et de la chlorpromazine en particulier, en psychiatrie. L 'Encéphale 1956; Numéro Spécia1:632–644
   Google Scholar
• Werner G: The central actions of chlorpromazine. L 'Encephale 1956; Numéro Spécia1:620–626
   Google Scholar
• Dell P, Bonvallet M, Hugelin A: Tonus sympathique, adrenaline et controle réticulaire de la motricité spinale. EEG Clin Neuro-physiol 1954; 6:599–618
   Google Scholar
• Hoffer A, Osmond H, Smythies J: Schizophrenia, a new approach. J Ment Sci 1954; 100:29–54
   PubMed Web of Science ®Google Scholar
• Woolley DW, Shaw F: A biochemical and pharmacological suggestion about certain mental disorders. Science 1954; 119:587–588
   Google Scholar
• Gottlieb JS, Frohnam CE: The biomedical identification of schizophrenia. In: Tourlentes IT, Pollock SL, Himwich HE, eds. Research approaches to psychiatric problems: A symposium. Nueva York: Grune and Stratton, 1992:129–139
   Google Scholar
• Carlsson A, Lindqvist M: Effect of chlorpromazine and halo-peridol on the formation of 3-methoxytrytamine and normeta-nephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20:140–144
   PubMedGoogle Scholar
• Snyder SH, Banerjee SP, Yamamura HL, Greenberg D: Drugs, neurotransmitters and schizophrenia. Science 1974; 184: 1243–1253
   PubMed Web of Science ®Google Scholar
• Rifkin A: Extrapyramidal side effects: a historical perspective. J Clin Psychiatry 1987; 48 (Suppl. 9):3–6
   Google Scholar
• Amat E, Cuenca E: Neuroleptics and monoamine oxidase inhibi-tors. Int Congr Series 1971; 319:38–48
   Google Scholar
• Labhardt F: Die Largactiltherapie bei Schizophrenien und anderen psychotischen Zuständen. Schw Arch Neurol Psychiatr 1954; 73:309
   PubMedGoogle Scholar
• Steck H: Le syndrome extra-pyramidal et diencéphalique au cours des traitements au Largactil et au Serpasil. Ann Méd Psy-chol 1954; 112:737–743
   PubMedGoogle Scholar
• Steck H: Le syndrome extrapyramidal dans les cures de chlorpro-mazine et Serpasil sa symptomatologie clinique et son role thérapeutique. L 'Encéphale 1956; Numéro Spécia1:783–789
   Google Scholar
• Broussolle P. Dubor P: Premier bilan des effets cliniques d'un nouveau neuroleptique. Comptes Rendus du 54 Congres des Médecins Aliénistes et Neurologistes de Langue Française 1956:482–490
   Google Scholar
• Delay J, Deniker P: Caractéristiques psycho-physiologiques des medicaments neuroleptiques. In: Delay J, Deniker P. eds. Psychotropic Drugs. Amsterdam: Elsevier, 1957:485–501
   Google Scholar
• Ayd FJ: A survey of drug-induced extrapyramidal reactions. J Am Med Assoc 1961; 175:1054–1060
   PubMed Web of Science ®Google Scholar
• Sigwald J, Bouttier D, Raymond C, Pichot P: Quartre cas de dys-kinésie, facio-bucco-linguo-masticatrice a l'évolution prolongée secondaire a un traitement par les neuroleptiques. Rev Neurol (Paris) 1959; 100:751–755
   PubMedGoogle Scholar
• Brooks GW: Experience with use of chlorpromazine and reserpine in psychiatry. New Eng J Med 1956; 254:1119–1123
   Google Scholar
• Kruse W: Parkinsonism, schizophrenia, and ataractic drugs. Dis Nerv System 1957; 18:474–477
   Google Scholar
• Haase HJ: "Extrapyramidal modifications of fine movements. A "condi° sine qua non" of fundamental therapeutic action of neu-roleptic drugs. Rev Can Biol 1961; 20:425–449
   Google Scholar
• Freyham FA: Relationship of drug-induced neurological phenomena on therapeutic outcome. Rev Can Biol 1961; 20:579–582
   Google Scholar
• Bishop MP, Gallant DM, Sykes TF: Extrapyramidal side effects and therapeutic response. Arch Gen Psychiatry 1965; 13:155–162
   PubMed Web of Science ®Google Scholar
• Delay J, Pichot P. Lemperiere T, et al: L'emploi des buty-rophénones en psychiatrie: étude statistique et psychométrique. Symposium Internazionale Sull'Haloperidol e Triperidol, 1962:305–319
   Google Scholar
• Caroff SN: The neuroleptic malignant syndrome. J Clin Psychi-atry 1980; 41:79–83
   PubMed Web of Science ®Google Scholar
• López-Mutioz F, Alamo C, Cuenca E: Aportación de la clorpro-mazina al desarrollo de la psiquiatria. Arch Psiquiatria 2003; 66:16–34
   Google Scholar